ArticleClinical and translational medicine2025

A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction-associated steatotic liver disease.

Shifang Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.